You are here: Home » Companies » News
Business Standard

Dr Reddy's halts worldwide supply of Ranitidine drug after probe by USFDA

Ranitidine is an Over-The-Counter (OTC) and prescription drug which decreases the amount of acid created by the stomach

Dr Reddys | drugs | USFDA

Press Trust of India  |  Hyderabad 

USFDA, drug maker, drugs, medicines
Representative Image

Dr Reddy's Laboratories Limited on Sunday said that it is suspending supply of its drug Ranitidine worldwide as a precautionary measure, following the ongoing probe by the US Food and Drug Administration into the reported impurity N-nitrosodimethylamine in it at low levels.

Ranitidine is an Over-The-Counter (OTC) and prescription drug which decreases the amount of acid created by the stomach.

"Dr.Reddys is still evaluating potential impact of the issue. As a precautionary measure, is suspending all shipments worldwide of Ranitidine products until the investigation (by the FDA) outcome is available.

We have both a prescription and an over-the-counter portfolio of the product," spokesperson told PTI in an email reply.

The FDA in a statement on September 13 had said it is working with international regulators and industry partners to determine the source of this impurity in Ranitidine and examining levels of NDMA in Ranitidine and evaluating any possible risk to patients.

Though the FDA is not calling for individuals to stop taking Ranitidine at this time, however, patients taking the prescription and wishing to discontinue its use should talk to their health care professionals about other treatment options, the US drug regulator said.

"We expect to provide an update in the coming days. The FDA is not calling for individuals to stop taking Ranitidine at this time.

Consumers and health care professionals should report any adverse reactions with Ranitidine to the FDA's MedWatch program to help the agency better understand the scope of the problem," said.

The FDA has been investigating NDMA and other nitrosamine impurities in blood pressure and heart failure medicines such as Valsartan since last year.

Aurobindo Pharma, Torrent Pharmaceuticals, Hetero Labs and many other multinationals have voluntarily recalled Valsartan from the USA market following the alleged cancer causing impurity-NDMA.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, September 22 2019. 12:05 IST